(Q64966958)

1 July 2019

title

Biomarkers as drug development tools: discovery, validation, qualification and use. (English)

1 reference

1 July 2019

1 reference

Virginia B Kraus

1

1 reference

1 July 2019

language of work or name

English

0 references

publication date

1 June 2018

1 reference

1 July 2019

Nature Reviews Rheumatology

published in

1 reference

1 July 2019

volume

14

1 reference

1 July 2019

issue

6

1 reference

1 July 2019

page(s)

354-362

1 reference

1 July 2019

Molecular Biology: Origin of the Term

cites work

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

The Importance of Biopsy in the Era of Molecular Medicine

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

A cerebrospinal fluid microRNA signature as biomarker for glioblastoma

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

Osteoarthritis year in review 2014: we need more biochemical biomarkers in qualification phase

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

The value of translational biomarkers to phenotypic assays

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

Stability study of 81 analytes in human whole blood, in serum and in plasma

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

The European Medicines Agency experience with biomarker qualification

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis.

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

Biomarkers in connective tissue diseases

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

Classification of osteoarthritis biomarkers: a proposed approach.

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

Serum markers of liver fibrosis: combining the BIPED classification and the neo-epitope approach in the development of new biomarkers

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

Molecular serum markers of liver fibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

Predictive validity of biochemical biomarkers in knee osteoarthritis: data from the FNIH OA Biomarkers Consortium

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

Measuring Disease Progression in Osteoarthritis

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

Generic prognostic factors for musculoskeletal pain in primary care: a systematic review.

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

FDA's Expedited Approval Mechanisms for New Drug Products

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

Viral load as a surrogate end point in HIV disease

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

Celecoxib pathways: pharmacokinetics and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

New "21st Century Cures" Legislation: Speed and Ease vs Science.

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

Active albuterol or placebo, sham acupuncture, or no intervention in asthma

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

Strategic paths for biomarker qualification

1 reference

https://api.crossref.org/works/10.1038%2FS41584-018-0005-9

7 January 2021

10.1038/S41584-018-0005-9

Identifiers

DOI

1 reference

1 July 2019

Dimensions Publication ID

1103969685

0 references

1 reference

1 July 2019